Intestinal Decontamination With Rifaximin. Effects on the Inflammatory and Circulatory State in Patients With Cirrhosis and Ascites - A Randomised Controlled Clinical Study

Trial Profile

Intestinal Decontamination With Rifaximin. Effects on the Inflammatory and Circulatory State in Patients With Cirrhosis and Ascites - A Randomised Controlled Clinical Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Rifamexil (Primary)
  • Indications Ascites; Liver cirrhosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Oct 2016 Primary endpoint has not been met. (Change from baseline in Hepatic venous pressure gradient (HVPG)), according to results published in the Hepatology.
    • 24 Oct 2016 Results published in the Hepatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top